NIAID supports a comprehensive portfolio of research covering basic, translational, and clinical studies to better understand the national history of tuberculosis (TB) and the development of drug resistance. NIAID also provides resources and animal models to investigators worldwide to facilitate biomedical research and help move drugs, vaccines, and diagnostics closer to patients.
Through the information offered here, researchers can learn about the science being conducted at NIAID and by NIAID-funded researchers. Researchers seeking funding can access opportunities to further their own research, while NIAID and NIH grantees can find out about available resources outside of specific funding opportunities. Recent publications, active networks, and ways to connect with other researchers are also available.
Latest News Releases
- World TB Day 2022—Invest to End TB. Save Lives
March 24, 2022
NIAID provides resources to the scientific community to advance basic through clinical research and support the development of vaccines, therapeutics, and diagnostics. Researchers do not need to be funded by NIH to access the resources. Available resources include repositories such as the BEI repository, genomics and emerging technologies, and clinical evaluation programs such as the Vaccine and Treatment Evaluation Units. Preclinical services available include the following:
- In Vitro Assessment for Antimicrobial Activity
- Preclinical Models of Infectious Diseases
- Therapeutic Development Services (including biopharmaceutical and interventional agent services)
- Vaccine Development Services (including manufacturing and testing services)
NIAID is always accepting researcher-initiated applications. Connect with NIAID program officers about potential or related funding for tuberculosis research.
- Dr. Karen Lacourciere, Acting Chief, Tuberculosis, Leprosy and Other Mycobacterial Diseases Section, Respiratory Diseases Branch
- Dr. Jim Boyce, Program Officer, Drug Discovery
- Dr. Katrin Eichelberg, Program Officer, Immunology and Vaccines
- Dr. Alison Kraigsley, Program Officer, Pathogen Biology
- Andre McBride, Health Specialist, Career Development
- Dr. Sudha Srinivasan, Program Officer, HIV-TB Clinical Research
- Dr. Daniel Frank, Program Officer, HIV-TB Clinical Research
NIAID supports a range of networks and programs to advance TB research, including the Immune Mechanisms of Protection Against Mycobacterium tuberculosis (IMPAc-TB) Centers. NIAID also encourages partnerships among other agencies and foundations, private industry, federal and local government and other organizations with similar goals to help build and sustain research infrastructure and to translate and implement research findings as public health practices.
Connect With Other Researchers
Researchers at NIAID
Much of the research conducted at NIAID on tuberculosis is done here:
- Clifton E. Barry III, Ph.D., Laboratory of Clinical Immunology and Microbiology
- Alan Sher, Ph.D., Laboratory of Parasitic Diseases
- Daniel L. Barber, Ph.D., Laboratory of Parasitic Diseases
- Katrin D. Mayer-Barber, Dr. rer. nat. (Ph.D.,) Inflammation and Innate Immunity Unit
Researchers Funded by NIAID
NIAID Strategic Plan for Tuberculosis Research
TB is the world’s leading infectious cause of death. In its strategic plan, NIAID details five strategic priorities for building on research advances to develop the knowledge and tools to end TB globally.
Anthony S. Fauci, Addressing the Tuberculosis Epidemic: 21st Century Research for an Ancient Disease Journal of the American Medical Association DOI: 10.1001/jama.2018.12852.
National Action Plan for Combating Multidrug-Resistant Tuberculosis
- National Action Plan for Combating Multidrug-Resistant Tuberculosis, Year Three Report
- National Action Plan for Combating Multidrug-Resistant Tuberculosis, Year Two Report
- National Action Plan for Combating Multidrug-Resistant Tuberculosis, Year One Report
- National Action Plan for Combating Multidrug-Resistant Tuberculosis: Six–Month Progress Report and Future Direction
- National Action Plan for Combating Multidrug-Resistant Tuberculosis